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Abstract
Background: The apolipoprotein E (APOE) gene exists in three isoforms in humans: APOE2, APOE3 and APOE4.
APOE4 causes structural and functional alterations in normal brains, and is the strongest genetic risk factor of the
sporadic form of Alzheimer’s disease (LOAD). Research on APOE4 has mainly focused on the neuronal damage
caused by defective cholesterol transport and exacerbated amyloid-β and Tau pathology. The impact of APOE4 on
non-neuronal cell functions has been overlooked. Astrocytes, the main producers of ApoE in the healthy brain, are
building blocks of neural circuits, and Ca2+ signaling is the basis of their excitability. Because APOE4 modifies
membrane-lipid composition, and lipids regulate Ca2+ channels, we determined whether APOE4 dysregulates
Ca2+signaling in astrocytes.
Methods: Ca2+ signals were recorded in astrocytes in hippocampal slices from APOE3 and APOE4 gene targeted
replacement male and female mice using Ca2+ imaging. Mechanistic analyses were performed in immortalized
astrocytes. Ca2+ fluxes were examined with pharmacological tools and Ca2+ probes. APOE3 and APOE4 expression
was manipulated with GFP-APOE vectors and APOE siRNA. Lipidomics of lysosomal and whole-membranes were
also performed.
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Results: We found potentiation of ATP-elicited Ca2+responses in APOE4 versus APOE3 astrocytes in male, but not
female, mice. The immortalized astrocytes modeled the male response, and showed that Ca2+ hyperactivity
associated with APOE4 is caused by dysregulation of Ca2+ handling in lysosomal-enriched acidic stores, and is
reversed by the expression of APOE3, but not of APOE4, pointing to loss of function due to APOE4 malfunction.
Moreover, immortalized APOE4 astrocytes are refractory to control of Ca2+ fluxes by extracellular lipids, and present
distinct lipid composition in lysosomal and plasma membranes.
Conclusions: Immortalized APOE4 versus APOE3 astrocytes present: increased Ca2+ excitability due to lysosome
dysregulation, altered membrane lipidomes and intracellular cholesterol distribution, and impaired modulation of
Ca2+ responses upon changes in extracellular lipids. Ca2+ hyperactivity associated with APOE4 is found in astrocytes
from male, but not female, targeted replacement mice. The study suggests that, independently of Aβ and Tau
pathologies, altered astrocyte excitability might contribute to neural-circuit hyperactivity depending on APOE allele,
sex and lipids, and supports lysosome-targeted therapies to rescue APOE4 phenotypes in LOAD.
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Background
Apolipoprotein E is a component of lipoproteins in-
volved in extracellular lipid transport and cholesterol
fluxes throughout the body, including the brain [1]. In
humans, APOE exists in three isoforms: APOE2, 3—the
most common allele—and 4. Although the three iso-
forms differ only in the amino acids in positions 112 and
158 at the N-terminal domain of the protein [2], this
minimal difference results in a structural change in the
APOE4 isoform that profoundly compromises its func-
tion [3], as shown by a wealth of studies in mice and
humans that document the impact of APOE genotype
on the structure and function of the healthy brain. Thus,
in humans, APOE4 is associated with reduced memory
retention [4], altered neural activity and brain connectiv-
ity [5], reduced grid-cell like representations [6], reduced
dendritic spine density [7], and hypometabolism mea-
sured with fluorodeoxyglucose-based PET [8]. Further-
more, APOE4 knock-in mice present alterations of
behavior, olfactory memory and neurotransmission, as
well as decreased dendritic arborization and metabolic
alterations [9–13], as compared to APOE3 knock-in
mice. Not only is normal brain function compromised
by APOE4, but APOE4 is also the strongest genetic risk
factor in late-onset Alzheimer’s disease (LOAD) [14], the
principal cause of age-related dementia, affecting
millions of people around the world [15]. A complex
interaction exists among sex, age and APOE4 load. Thus,
according to a meta-analysis, heterozygous APOE3/
APOE4 women present increased risk of LOAD between
the ages of 65 and 75 years, and increased risk of mild
cognitive impairment (MCI) between the ages of 55 and
70, as compared to men [16]. Homozygous APOE4 sub-
jects show increased risk compared to APOE3/APOE4
heterologous individuals [16–18], with men being at
greater risk as reviewed by Riedel and colleagues [17]
but not according to other authors [18]. In addition, det-
rimental actions of APOE4 have been reported in other
neurodegenerative disorders such as frontotemporal de-
mentia [19], cerebrovascular disease [20] and traumatic
brain injury [21].
The mechanisms whereby APOE4 is pathological in
normal and diseased brain are not totally clarified [15].
An outstanding question is whether APOE4 affects the
function of brain cells other than neurons. Although
microglia and neurons secrete ApoE in pathological con-
ditions, as described in mouse neurons injured with
kainic acid [22], and in human LOAD brains, where
microglia produces and deposits ApoE in senile plaques
[23] and appears to mediate Tau pathology [24], it is
often overlooked that APOE is mainly synthesized, se-
creted, and lipidated by astrocytes in physiological and
pathological conditions [3]. Astrocytes can also take up
lipoproteins, as they express APOE receptors such as the
LRP1 receptor [25].
Astrocytes are building blocks of neural circuits, where
they modulate neuronal activity [26]. Apart from the im-
pact of APOE4 on synaptogenesis [27] and synaptic
transmission [28] by lowering the delivery of cholesterol
from astrocytes to neurons, the question of whether
APOE4 compromises the global control of astrocytes
over neuronal activities has not been examined. Among
phenomena modulated by astrocytes there are, to cite a
few, long-term potentiation (LTP), memory consolida-
tion, and circadian rhythms [29–32]. Central to
astrocyte-to-neuron communication is Ca2+ signaling in
astrocytes. Thus, although astrocytes are considered
non-excitable cells in terms of action potentials, they re-
spond by way of Ca2+ signals to neurotransmitters. In
turn, such Ca2+ responses promote the release of several
molecules called gliotransmitters, such as ATP, glutam-
ate, D-serine or GABA [29, 30, 32–34]. Ca2+ signaling is
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thus considered the basis of astrocyte excitability, which
is exquisitely precise owing to unique spatiotemporal
Ca2+ features resulting from the combination of Ca2+
signaling pathways orchestrated by different second
messengers, and intracellular organelles [35]. Pathways
include inositol 1,4,5-triphosphate (IP3)-mediated Ca2+
release from the endoplasmic reticulum (ER) [36], and
nicotinic acid adenine dinucleotide phosphate
(NAADP)-elicited mobilization from acidic organelles, a
heterogeneous population of vesicles highly enriched in
lysosomes [37]. Extracellular Ca2+ entry and mitochon-
drial Ca2+ uptake can further shape cytosolic Ca2+ in-
creases [37, 38]. Of note, dysregulation of Ca2+ signaling
in astrocytes has been reported in animal models of
LOAD [39]. However, Ca2+ signaling has never been
studied in astrocytes in the context of APOE4.
APOE genotype confers distinct composition to lipid
membranes [40], and it is well established that lipid
composition (e.g., contents of cholesterol and phospho-
lipids) affects the function of membrane-associated
enzymes, receptors, and channels [41]. On the basis of
this evidence, we posited that APOE4 dysregulates Ca2+
excitability in astrocytes by modifying membrane lipid
composition. To test this hypothesis, we studied ex vivo
Ca2+ signaling in hippocampal astrocytes of female and
male mice with human APOE3 and APOE4 gene
targeted replacement of the endogenous mouse APOE
[42, 43]. We found that Ca2+ responses induced by the
stimulation of purinergic receptors were upregulated in
APOE4 versus (vs) APOE3 astrocytes in male, but not in
female mice. Next, we clarified the underlying mecha-
nisms in cultured immortalized astrocytes expressing
human APOE3 and APOE4 [44]. The cells reproduced
the ex vivo model of male mice, as Ca2+ responses were
increased in immortalized APOE4 cells as compared to
APOE3 cells. Cultured APOE4 astrocytes released more
Ca2+ from their acidic stores upon purinergic stimula-
tion. Manipulation of APOE4 and APOE3 expression re-
vealed that it is the allele, not the reduced synthesis, that
caused altered Ca2+ signaling in immortalized APOE4
astrocytes. Finally, we demonstrated that APOE4 astro-
cytes have distinct lipidome and were refractory to con-
trol Ca2+ fluxes by extracellular lipids. Taken together,
the data suggest that the APOE genotype modulates
Ca2+ fluxes in astrocytes in a lipid, lysosome and sex-
dependent manner. Future research will clarify whether
dysregulation of astrocyte excitability contributes to the
increased risk of developing LOAD and other brain
pathologies in APOE4 carriers.
Materials and methods
Animal model
Nine- to 12-week-old male and female APOE3 and
APOE4 transgenic mice homozygous for the human
APOE3 or APOE4 gene replacing the endogenous mouse
APOE gene were purchased from Taconic (USA) [42,
43]. All experimental procedures were performed ac-
cording to the animal research regulations (RD53/2013
and 2010/63/UE) of Spain and the European Union, and
with the approval of the Committees of Animal Research
from the Institutional Animal Ethics Committee of
CSIC. Animals were housed in standard laboratory cages
with ad libitum access to food and water, under a 12:12
h dark-light cycle in temperature controlled rooms.
Cell culture
APOE3 and APOE4 immortalized astrocytes were a gift
from Dr. Holtzman (Washington University) [44]. Im-
mortalized astrocytes were routinely grown at 37 °C in
5% CO2 humidified atmosphere air in advanced DMEM
medium supplemented with 1 mM of Na+ pyruvate, 10%
fetal bovine serum (FBS), 100 U/mL of penicillin,
100 μg/mL of streptomycin, and 0.2 mg/ml of geneticine.
Cell passages were performed with trypsin once per
week up to passage 10.
Ca2+ imaging in astrocytes ex vivo in brain slices
Animals were sacrificed; the brain was rapidly removed
and placed in ice-cold modified artificial cerebrospinal
fluid medium (ACSF). To reduce swelling and damage
in superficial layers, N-methyl-D-glucamine (NMDG)-
ACSF was used during brain sectioning, NMDG being a
substitute for sodium ions in a wide range of adult ages
and applications [45]. NMDG-ACSF contained [in mM]:
NMDG 93, KCl 2.5, NaH2PO4 1.2, NaHCO3 30, HEPES
20, MgSO4 10, CaCl2 0.5, glucose 25, sodium ascorbate
5, thiourea 2, sodium pyruvate 3, gassed with 95% O2/
5% CO2 (pH 7.3–7.4). Hippocampal slices (350 μm) ob-
tained with a vibratome (Leica Vibratome VT1200S,
Germany) were incubated in NMDG-ACSF for 10 min
at 34 °C, and then equilibrated for more than 1 h at
room temperature (22–24 °C) prior cell loading with
fluorochromes in ACSF containing [in mM]: NaCl 124,
KCl 2.69, KH2PO4 1.25, MgSO4 2, NaHCO3 26, CaCl2 2,
and glucose 10, gassed with 95% O2/5% CO2 (pH 7.3–
7.4). Slices were loaded with sulforhodamine 101
(SR101, 1 μM) for 20 min at 34 °C for astrocyte labeling
[46–48], and washed in ACSF for 10 min at 34 °C. After
SR101 labeling, slices were loaded with 2 mM of fluo-4/
AM for 20–30 min at room temperature. After washing
fluo-4/AM overloading in ACSF, slices were kept in
ACSF medium supplemented with 10% FBS at the stage
of a Nikon Eclipse FN1 microscope coupled to a CCD
camera (ORCA-R2, Hamamatsu, Japan). Cells were illu-
minated for 100–200 ms at 490 nm using LED system
(CoolLED pE-100), and images from stratum radiatum
astrocytes were acquired every 1 s. The LED system and
the camera were controlled and synchronized by the
Larramona-Arcas et al. Molecular Neurodegeneration           (2020) 15:35 Page 3 of 23
NIS-Elements software (Nikon, Japan) that was also used
for epifluorescence measurements. Astrocyte Ca2+ levels
were recorded from the astrocyte cell body, and Ca2+
variations were quantified as changes in the fluorescence
signal (F) over the baseline (F0) ((F-F0)/F0). Two proto-
cols of Ca2+ monitoring were used. Firstly, spontaneous
events were studied by recording Ca2+ events for 120 s.
Secondly, ATP-induced responses were studied by re-
cording Ca2+ baseline for 30 s, followed by local applica-
tion of ATP (1 mM; 5 s) to activate purinergic receptors
for 30 s, and post ATP period for 60 s. Local application
of ATP was delivered by pressure pulses through a
micropipette (Picospritzer II, Parker Hannifin, Mayfield
Heights, OH, USA) in the presence of tetrodotoxin
(TTX, 1 μM). Matlab software (MATLAB R2016; Math-
works Natick) custom-written plugin was used for com-
putation of fluorescence values of each region of interest
(ROI).
Ca2+imaging in astrocytes in vitro in immortalized
astrocytes
Intracellular Ca2+ measurement was performed using
2 μM of fura-2/AM, a ratiometric fluorescence indicator
whose fluorescence ratio (R340/380) is proportional to
Ca2+ concentration. Imaging of Ca2+ signaling in organ-
elles was performed using genetically encoded Ca2+ indi-
cators (GECI). The plasmids for endoplasmic reticulum
(pCMV G-CEPIA1er) and mitochondrial (pCMV
CEPIA3mt) were a gift from Masamitsu Iono [49].
Fluorescence was recorded using a TE-2000 U Nikon
epifluorescence microscope keeping the cells at 37 °C.
Cells were excited with a monochomator (Cairns, UK)
and the emitted fluorescence was collected every 2 s by
the high sensitivity CCD EG-ORCA camera (Hamama-
tsu Photonics, Japan) using a 40x oil objective (Nikon,
Japan). The resulting images were analyzed through
MetaFluor Software (Universal Imaging, Bedford Hills,
NY, USA). For experiments using fura-2/AM, the ratio
between fluorescence after excitation at 340 and 380 nm
was calculated, whereas for experiments using GECI the
fluorescence of the CEPIA indicators at a given time
point was normalized to the initial fluorescence (F/F0).
Ratiometric fluorescence values were obtained using the
MetaFluor software and selecting individual cells (ROI).
Two to four coverslips with 15 to 25 cells per coverslip
were analyzed for each condition. Data values were
further analyzed with GraphPad Prism 6.
Plasmid transfection and siRNA silencing
Cells were transfected with plasmids using Lipofecta-
mine 2000 (Thermo Fisher Scientific) while transfection
with siRNA to achieve silencing was accomplished with
Lipofectamine RNAiMAX (Thermo Fisher Scientific).
Briefly, lipofectamine and DNA or siRNA were added to
medium without FBS and antibiotics. This solution was
kept at room temperature for 20 min and administered
to the cells. After 5 h, the medium was replaced by
growth medium. The quantities of lipofectamine and
DNA or siRNA were: 9 μL of lipofectamine and 2.5 μg/
mL GECI plasmids; 12 μL of lipofectamine and 4.5 μg/
mL of APOE plasmids (described in [50]), and 4.5 μL of
lipofectamine and 1 μg/mL of APOE siRNA (s194291,
Thermo Fisher Scientific) or negative control 1 μg/mL
siRNA (Thermo Fisher Scientific).
Lysosomal pH measurement
Lysosomal pH was measured using the ratiometric dye
LysoSensor Yellow/Blue DND-160 (Thermo Fisher
Scientific) as described [51] with minor modifications.
Briefly, cells were incubated with 2 μM of LysoSensor
Yellow/Blue in an isotonic solution with addition of 10%
FBS. Next, cells were incubated with either additional
isotonic solution for pH measurement, or with pH cali-
bration buffers with the corresponding FBS content to
perform a standard curve for each condition. 15 μM of
monensin and 30 μM of nigericin were added to the pH-
calibration solutions to force lysosomal pH to equilibrate
with a range of pH values (solutions at 4.0, 4.5, 5.0, 5.5
and 6.0 pH). Fluorescence was measured with a GENios
Pro Fluorometer, and recorded using the XFluor4GEN-
iosPro software package (TECAN). Lysosomal pH was
determined from the ratio of excitation light at 340 nm
and 390 nm (collection emission at 535 nm) after
extrapolation with the standard curve.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15 min
and permeabilized by adding 0.1% of Triton buffer.
Then, 5% of normal goat serum (NGS) was used to
block the unspecific unions. Primary antibodies (mouse
monoclonal anti-ApoE (sc53570, Santa Cruz Biotechnol-
ogy, dilution 1:400) and rat monoclonal anti-Lamp1
(1D4B, Hybridoma Bank, dilution 1:200) were incubated
overnight, followed by one-hour incubation with the sec-
ondary antibody Cy3-donkey anti-rat IgG (712–165-150,
Jackson Immunoresearch, dilution 1:200) and Alexa
fluor 488 goat anti-mouse IgG (A11029, Thermo Fisher
Scientific, dilution 1:1000). Coverslips were mounted on
a slide with Fluoromount G. Images were acquired with
confocal laser scanning microscopy ZEISS LSM 700.
Analysis of lysosome localization was carried out using
the ImarisCell tool of IMARIS software (Bitplane), which
permits manual selection of the nucleus and the mem-
brane of each cell and computes the distance (μm) from
each Lamp1-positive vesicle to the nucleus center.
Lamp1-positive vesicles larger than 0.5 μm were consid-
ered. The frequency distribution of vesicles from the nu-
cleus center to the cellular membrane was represented.
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Cholesterol staining
Filipin III (Sigma-Aldrich) was used to stain cholesterol.
Cells were fixed with 4% paraformaldehyde for 15 min
and incubated with 25 μg/mL Filipin for 30 min at room
temperature in the dark. Images were acquired with a
CCD ORCA-EG monochromatic camera (Hamamatsu)
and the Eclipse TE-2000E (Nikon) epifluorescence
microscope, using a 20x objective.
Lysosomal isolation
Lysosomes from astrocytes were isolated as described
[52]. Briefly, collected cells were washed in sucrose 0.25
M (pH 7.2) and disrupted in a nitrogen cavitation
chamber (Kontes Glass Company), followed by
homogenization in a Teflon-glass homogenizer and
centrifuging (2500 xg for 15 min). The mitochondria-
lysosomal-enriched faction was collected after 17,000 xg
centrifugation. The lysosomal-mitochondrial-enriched
fraction was then loaded in two subsequent discontinu-
ous metrizamide/sucrose/percoll density gradients from
which lysosomal pure fractions were isolated [52]. Lyso-
somes were broken by 5 consecutive freeze/thaw cycles
and after centrifugation at 100.000 xg 30 min, lysosomal
membrane and intralysosomal content were collected
separately. The former pool was used for lipidomic
analysis.
Lipidomics
The extraction of metabolites for the untargeted lipido-
mic assay was carried out by adding 200 μL CHCl3:
MeOH in a proportion of 1 to 2 with 0.1% formic acid
to promote the ionization of molecules. Then, samples
were vortexed, centrifuged at 4000 rpm, and analyzed
with mass spectrometry using the QSTAR XL hybrid
system (Applied Biosystems, Foster City, CA, USA). The
sample was injected at a flux of 15 μL/min through the
infusion integrated pump. Spectra were acquired during
positive ionization in a range of m/z from 50 to 1100
uma. The ionization parameters were: 3300 V of voltage
ion spray, 60 V of decluttering potential, and 250 V of
focusing potential. Nitrogen was used as a collision gas
for the spectra acquisition. Markerview™ and SIMCA-P™
software were used to reduce the results into a two-
dimensional matrix of peak spectra and intensity of
peaks, and for the statistical analysis. Inter-genotype
comparisons were carried out with the multivariate
analysis Partial Least Squares-discriminant analysis
(PLS-DA). Next, the Variable Importance in Projection
(VIP) was used to establish which metabolites had more
impact in the segregation of samples according to
APOE3 and APOE4 genotypes. ANOVA with a Tukey
correction post-test was applied to the group of metabo-
lites with a VIP > 1 to assess, again, inter-genotype
differences with the identified metabolites. We then
proceeded to identify metabolites with VIP > 1 compar-
ing their accurate masses with those available in metabo-
lomics databases (HMDB, METLIN, KEGG and
LIPIDMAPS) [53]. Finally, fold changes of identified me-
tabolites in APOE4 vs APOE3 astrocytes were calculated
and a multi-t statistical test with corrected probability
(False Discovery Rate –FDR- 5%) was applied.
Western blot
Cells for protein extraction were lysed with RIPA buffer
and extracts were sonicated and centrifuged. Protein ex-
tracts were quantified with BCA kit (23,225, Thermo
Fisher Scientific) according to the manufacturer’s proto-
col. 20 μg protein of samples was loaded in 12% poly-
acrylamide gels electrophoresis (PAGE). Electrophoresis
was conducted at a constant amperage (30 mA) for ap-
proximately 2 h followed by the protein transference to a
PVDF membrane at constant voltage (100 mV) for 1.5 h.
5% non-fat milk was used to block unspecific unions,
and the primary antibodies mouse monoclonal anti-V-
ATPase subunit V0D1 (ab56441, Abcam, used at 2.5 μg/
mL) and monoclonal anti β-actin (a5316, SigmaAldrich,
used at 1/20000), were incubated overnight. The next
day, the secondary antibody was incubated for 1 h (goat
anti-mouse IgG: 31430, Thermo Fisher Scientific, used
at 1/10000). Finally, the membrane was developed using
the chemiluminescence kit of BioRad according to the
manufacturer’s protocol, and membrane chemilumines-
cence was detected with a Chemidoc MP Image System
(BioRad). Image lab software (BioRad) was used for the
quantification of bands.
Measurement of mRNA expression
Cells were collected adding Trizol Reagent. Then, 0.2
mL chloroform was added to the extracts, and these
were centrifuged at 11,500 rpm for 15min at 4 °C allow-
ing the formation of three phases. The RNA-containing
phase (superior phase) was isolated by pipetting care-
fully, and 0.2 mL of isopropanol was added to precipitate
of RNA, which was then washed with cold ethanol 75%.
RNA-sample concentration was determined with a
Nanodrop 200 spectrophotometer (Thermo Fisher
Scientific). 2 μg of RNA was reverse transcripted to
cDNA using 1 μM of oligo DT, 1 μM of hexamers, 0.5
mM dNTPs, 0.45 mM DTT, 10 U RNAse out, RT buffer,
and 200 U of retrotranscriptase. The PCR program was
divided into four steps: 65 °C for 10 min, 25 °C for 10
min, 42 °C for 1 h, and 72 °C for 10 min.
Gene expression was carried out with quantitative
real-time PCR (qPCR) using Taqman and SYBR green
technology. Fluorescence was detected with the 7500
Fast Real-Time PCR System. qPCR cycles were the fol-
lowing: a holding stage of 50 °C (2 min), 10 min at 95 °C
and 40 cycles of 95 °C (15 s), and 60 °C (1 min). A similar
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protocol was used for SYBR assay but with an extra
stage for the melting curve (15 s at 95 °C, 1 min at 60 °C,
30 s at 95 °C, and 15 s at 60 °C). Data analysis was
performed using Cq value, and the average of the gene
efficiency provided by LinReg PCR software, following
the formula 1 + eficienceΛCq of each gene analyzed.
Expression data were normalized with housekeeping
genes (Gapdh and/or18s), using their geometric mean
calculated according to the geNorm algorithm [54].
TaqMan primers of APOE (Hs00171168_m1), Trpml
(Mm00522550_m1), Gapdh (Mm9999915_g1), and 18S
(Mm03928990) were purchased from Thermo Fisher
Scientific. Primers for SYBR green were designed
according to the sequence of the gene: Tpc1 (5′-CTGG
GAGAGATGAATTATCAAGAG-3′; 5′-GTTGTGTAC-
GAAGAGGTAGG-3′), Tpc2 (5’GCTGAGCCTTGCTT
GTGAGG-3′; 5′-ACACTTCAGGGTCTTCTTCATCA-
3′), and Gapdh (5′-AAGCTCATTTCCTGGTATGAC-
3′; 5′-TGGTCCAGGGT TTCTTACTC-3′).
Statistical analysis
Each determination was carried out with cells from at
least three different passages. A parametric unpaired T-
test was used for the comparison of a given variable in
two different conditions or cell types, whereas one-way or
two-way analysis of variance (ANOVA), with a Tukey’s or
Dunn’s post hoc test, was used when comparing more
than two conditions. The software employed was Graph-
Pad Prism 6, and data are represented as mean ± SEM
(standard error of the mean). A p-value < 0.05 was consid-
ered significant (p-value < 0.05 (*), p-value < 0.01 (**), p-
value < 0.001 (***) and p-value < 0.0001(****).
Results
APOE4 expression alters astrocytic excitability
To determine whether expression of the allele APOE4
alters astrocyte excitability, we recorded Ca2+ in hippo-
campal slices of 9–12-week-old male and female mice in
which the endogenous mouse APOE gene had been re-
placed with human APOE3 or APOE4 genes. Recordings
were made in ACSF medium supplemented with 10%
FBS, in order to keep lipoprotein and lipid concentration
as close as possible to physiological conditions. Slices were
incubated with the Ca2+ indicator fluo-4/AM and the
astrocytic marker sulforhodamine (SR101) (Fig. 1a, see
Materials and methods). We analyzed Ca2+ spontaneous
activity—that is, Ca2+ events at rest conditions—and
neurotransmitter-induced Ca2+ responses in cells co-
labeled with Fluo-4/AM and SR101. To study spontan-
eous activity, we recorded APOE3 and APOE4 astrocytes
for 120 s. For receptor-mediated Ca2+ responses, we re-
corded basal peak activity for 30 s, and then we stimulated
slices with 1mM ATP. We selected purinergic stimulation
because it elicits Ca2+ signals both in astrocytes in vivo
and in vitro, triggering several physiological functions [34,
55], and because responses elicited by stimulation of
purinergic receptors are the cause of Ca2+ hyperactivity in
AD mouse models [56].
In male mice, we detected increased amplitude of
spontaneous Ca2+ transients in APOE4 vs APOE3 astro-
cytes (Fig. 1b). Regarding induced activities, purinergic
stimulation caused in both genotypes the increase in
magnitude and frequency of Ca2+ transients typically
seen in astrocytes. The amplitude of Ca2+ responses was
greater in APOE4 cells than in APOE3 cells (Fig. 1c and
d). Further, the magnitude of Ca2+ responses decreased
after removal of ATP (post ATP phase) to basal levels in
APOE3 astrocytes, but remained significantly increased
over its own basal levels, and with respect to APOE3
cells, in APOE4 cells (Fig. 1c and d). The frequency of
Ca2+ responses was similar in both genotypes, in both
the ATP and post-ATP phases. It is worth stressing that
the amplitude of spontaneous Ca2+ transients was also
statistically increased in APOE4 compared to APOE3
cells in these set of experiments, confirming the results
of the 120-s recordings (Fig. 1c and d).
Female mice differed from males in two respects. First,
the amplitude of spontaneous and ATP-induced events
was significantly increased (p < 0.001), by at least 2-fold,
in astrocytes from APOE3 females as compared to
APOE3 males (compare Fig. 1b with 2a and 1d with 2c).
Second, no differences were observed between APOE3
and APOE4 astrocytes in females in the magnitude of
spontaneous and induced events (Fig. 2a-c). This may
suggest that Ca2+ responses in astrocytes from APOE3
females represented the maximal Ca2+ response that
could not increase further. Altogether, the ex vivo obser-
vations suggest that expression of human APOE alleles
modulates Ca2+ transients in astrocytes in a sex-specific
manner, such that expression of the APOE3 allele in
male mice results in globally decreased Ca2+ transients
in astrocytes—or expression of APOE3 in females in a
global increase—as compared to the APOE4 allele.
Immortalized APOE4 astrocytes show increased Ca2+
mobilization from acidic stores
To gain insight into the mechanism by which expression
of different APOE alleles regulates Ca2+ transients in as-
trocytes, we used immortalized astrocytes that express
human APOE3 or APOE4 [44] since this in vitro model
allows for experimental manipulations that are not feas-
ible in brain slices. As with slices, cells were supple-
mented with 10% FBS, in order to keep lipoprotein and
lipid concentration as close as possible to physiological
conditions. It is worth stressing that immortalized astro-
cytes are aneuploid so the sexual identity is lost. Thus, a
key question was whether their Ca2+ phenotype is male-
or female-like. Our data show that they reproduce a
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male-like Ca2+ signaling phenotype in the presence of
lipids. First, differences in Ca2+ responses at rest showed
the same trend observed in male mice. APOE4 astrocytes
had significantly different Ca2+ basal levels than APOE3
astrocytes (p-value = 0.01), the fluorescence ratio being
0.28 ± 0.01 and 0.41 ± 0.03, respectively (Fig. 3a-c). Note
that cultured astrocytes do not show at rest the so-called
spontaneous Ca2+ oscillations observed ex vivo, but
stable basal Ca2+ levels that we could compare thanks to
the ratiometric fura-2/AM Ca2+ indicator. Second,
100 μM ATP stimulation resulted in greater Ca2+ re-
sponses in APOE4 than in APOE3 astrocytes (Fig. 3a).
Purinergic-induced Ca2+ responses also lasted longer:
the response was 64.9 ± 8.2% of the maximum peak sig-
nal after 20 s in APOE4 cells but only 27.7 ± 1.5% in
APOE3 astrocytes. Moreover, altered Ca2+ signaling was
not restricted to purinergic stimulation, as adrenergic
and muscarinic-receptor activation also triggered greater
cytosolic Ca2+ responses in APOE4 than in APOE3 as-
trocytes (Fig. 3b and c). Importantly, the magnitude of
Fig. 1 Enhanced Ca2+ signals in astrocytes from male APOE4 vs APOE3 targeted replacement mice. a Astrocyte from stratum radiatum of
hippocampus of male mice labeled with SR101 (red), fluo-4/AM (green), and merged image. Scale bar represents 10 μm. b Spontaneous Ca2+
activity in astrocytes from APOE3 (N = 36 astrocytes) and APOE4 male mice (N = 16 astrocytes). Ca2+ was monitored for 120 s without any
stimulation. c Left panels, raster plots of Ca2+ activity in APOE3 (upper panel, N = 146 astrocytes), and APOE4 male mice (lower panel, N = 171
astrocytes). The color code indicates relative fluorescence changes before and after local application of ATP (arrow, 5 s, 1 mM). Right panel,
representative traces of Ca2+ signals evoked by an ATP puff in APOE3 (top) and APOE4 (bottom) astrocytes (arrows indicate ATP stimulation). d
Quantification of the amplitude and frequency of Ca2+ events for 30 s before (basal peaks), during (ATP) and after local application of stimulus
(post-ATP). Statistical significance was established at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***); One-way ANOVA followed by Dunn’s post hoc
test. All the experiments were performed in the presence of TTX (1 μM). N = 4 mice, for both APOE3 and APOE4
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purinergic-induced Ca2+ responses was the same with
two other FBS batches (peak responses after stimulation
with 100 μM ATP were 0.36 ± 0.13 in APOE3 and 0.94 ±
0.01 in APOE4; and 0.37 ± 0.04 in APOE3 and 0.91 ±
0.05 in APOE4 astrocytes). Taken together, the data
support immortalized APOE3 and APOE4 astrocytes as a
model to study the mechanisms underlying the regula-
tion of Ca2+ responses by APOE alleles in males.
Next, in order to identify which pathways are dysregu-
lated in APOE4 astrocytes, we examined Ca2+ fluxes
among the principal intracellular Ca2+ sources with
organelle-specific probes and pharmacological manipula-
tions. First, we investigated the mitochondrial Ca2+ up-
take that characteristically buffers increases in cytosolic
Ca2+. Since APOE4 has been described as harming mito-
chondria in neurons [57], we reasoned that harmed
mitochondria in APOE4 astrocytes could result in defi-
cient Ca2+ uptake, and hence in increased intracellular
Ca2+ responses. However, expression of the mitochon-
drial Ca2+ indicator CEPIA3mt (Fig. 3d) showed higher
Fig. 2 Equal Ca2+ signals in astrocytes from female APOE3 and APOE4 targeted replacement mice. a Spontaneous Ca2+ activity in astrocytes from
APOE3 (N = 26 astrocytes) and APOE4 female mice (N = 35 astrocytes). Ca2+ was monitored for 120 s without any stimulation. b Left panels, raster
plots of Ca2+ activity in astrocytes from APOE3 (upper panel, N = 165 astrocytes), and APOE4 female mice (lower panel, N = 124 astrocytes). The
color code indicates relative fluorescence changes before and after local application of ATP (arrow, 5 s, 1 mM). Right panel, representative traces
of Ca2+ signals evoked by an ATP puff in APOE3 (upper panel) and APOE4 (bottom panel) astrocytes (arrows indicate ATP stimulation). c
Quantification of the amplitude and frequency of Ca2+ events for 30 s before (basal peaks), during (ATP) and after local stimulus (post-ATP) in
APOE3 and APOE4 astrocytes. Statistical significance was established at p < 0.001 (***); One-way ANOVA followed by Dunn’s post hoc test. All the
experiments were performed in the presence of TTX (1 μM). N = 4 mice, for both APOE3 and APOE4
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Ca2+ uptake in APOE4 mitochondria compared to
APOE3 astrocytes, consistent with the higher ATP-
induced Ca2+ responses in the cytosol (Fig. 3e). Second,
we studied the main Ca2+ signaling pathway in astro-
cytes, Ca2+ mobilization from the ER through the IP3 re-
ceptor, by transfecting cells with G-CEPIA1er (Fig. 3d),
and directly measuring Ca2+ contents inside this organ-
elle. As expected, 100 μM ATP decreased Ca2+ levels in
the ER of both APOE3 and APOE4 astrocytes, indicative
of Ca2+ being released to the cytosol. Since the process
is, although significantly, just slightly reinforced in
APOE4 astrocytes (Fig. 3f), the greater cytosolic Ca2+
responses in these cells could not rely exclusively on
increased Ca2+ mobilization from the ER. Third, we
explored Ca2+ mobilization from acidic stores, which are
mainly lysosomes and related organelles [58] that we
have shown to be involved in purinergic-induced Ca2+
responses in astrocytes [37]. Figure 4a shows the main
Ca2+ fluxes in lysosomes. We recorded cytosolic Ca2+
with fura-2/AM, after inhibiting Ca2+ release from acidic
stores with 100 μM of Ned-19, an inhibitor of NAADP
receptors responsible for Ca2+ release from these organ-
elles [59]. Control cells were treated with DMSO, the
vehicle of Ned-19. As expected, Ned-19 reduced ATP-
induced Ca2+ responses in APOE3 cells (Fig. 4b),
confirming the contribution of lysosomal Ca2+ to cyto-
solic transients [37]. Interestingly, Ned-19 greatly
reduced Ca2+ responses in APOE4 astrocytes, such that
purinergic-mediated Ca2+ responses in the presence of
Ned-19 were of similar magnitude in both cell types.
Fig. 3 Enhanced Ca2+ signals in immortalized astrocytes from APOE4 vs APOE3 targeted replacement mice. Ca2+ responses measured using fura-
2/AM in APOE3 and APOE4 astrocytes after stimulation with (a) 100 μM ATP, (b) 10 μM noradrenaline (NA), and (c) 100 μM acetylcholine (Ach).
Representative traces and quantification of the magnitude of the responses are shown (N = 4 for a and c, and N = 3 for b). d Images of astrocytes
transfected with the Ca2+ probes for mitochondria (CEPIA3mt) and ER (G-CEPIA1er). Scale bar represents 15 μm. e Representative traces and
quantification of mitochondrial Ca2+ in APOE3 and APOE4 cells transfected with CEPIA3mt upon stimulation with ATP (N = 3). f Representative
traces and quantification of the decrease in ER Ca2+ upon stimulation of purinergic receptors in APOE3 and APOE4 cells transfected with
GCEPIA1er (N = 5). Unpaired parametric T-test was used to compare responses in APOE3 vs APOE4 astrocytes. p < 0.05 (*), p < 0.01 (**),
p < 0.001 (***)
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Hence, Ca2+ release from acidic-stores appears to be re-
sponsible for the greater purinergic-elicited Ca2+ re-
sponses in APOE4 astrocytes. Altogether, our results
thus far lend support to the idea that lysosomal-related
Ca2+ release is the main Ca2+ signaling pathway dysregu-
lated in APOE4 astrocytes.
Dysregulation of V-ATPase activity contributes to the
alteration of Ca2+ responses in APOE4 astrocytes
Ca2+ is released from acidic stores upon stimulation of
NAADP receptors, which are Ca2+ channels, the most
accepted candidates being two-pore channels 1 and 2
(Tpc1, Tpc2), and transient receptor potential mucolipin
(Trpml) [59]. By contrast, Ca2+ uptake by acidic stores is
accomplished through an indirect mechanism whereby
V-ATPase pumps H+ into the vesicles, and then H+ are
exchanged with Ca2+ through the Ca2+/H+ exchanger
(CAX) [60] (Fig. 4a). Thus, greater Ca2+ release from
acidic stores in APOE4 astrocytes might be due to two
phenomena: greater expression or activation of NAADP
receptors, or greater Ca2+ stored in these organelles, due
to increased activity of V-ATPase and/or CAX. First, we
Fig. 4 Dysregulated Ca2+ excitability in APOE4 immortalized astrocytes is due to greater lysosomal V-ATPase activity. a Schematic of the lysosomal
Ca2+ mobilization and uptake mechanisms. b Representative traces and quantification of ATP-induced cytosolic Ca2+ responses of cells treated
with 0.1% DMSO or 100 μM Ned-19 (diluted in 0.1% DMSO) for 20 min (N = 3). c Quantification by real time qPCR of mRNA expression of Tpc1
and Tpc2 (normalized to Gapdh mRNA contents, N = 5) and Trpml (normalized to Gapdh mRNA contents, N = 4). d Representative traces and
quantification of the area under the curve (AUC) of intracellular Ca2+ after lysing the lysosomes with 200 μM GPN (N = 4). e Representative traces
and quantification of ATP-induced Ca2+ responses after treating cells with DMSO or 2 μM bafilomycin A1 (Baf) for 20 min (N = 3). Note that the
black arrow indicates differences in basal Ca2+. f Quantification of V-ATPase subunit V0D1 with western blot, normalized to β-actin expression (N =
4). g Quantification of the pH of acidic organelles in APOE3 and APOE4 astrocytes (N = 3). Unpaired parametric T-test was used, except in b and e,
where one-way ANOVA was used. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)
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analyzed the expression of NAADP receptors in astro-
cytes with real time qPCR. Expression of Trpml and
Tpc1 channels is the same in APOE3 and APOE4 cells,
while expression of Tpc2 channel is lower in APOE4
cells (Fig. 4c), perhaps as a result of a negative feedback
mechanism in response to the high Ca2+ signals in
APOE4 astrocytes. In any event, the increased release of
Ca2+ from APOE4 lysosomes cannot be attributed to in-
creased expression of NAADP receptors.
Second, we analyzed Ca2+ contents inside acidic stores
with a protocol in which they were osmotically lysed due
to the accumulation of the peptide Glycyl-L-phenylalanine
2-naphthylamide (GPN), followed by its proteolysis by ca-
thepsin C, such that the stored lysosomal Ca2+ is released
into the cytoplasm. Then, the area under the curve (AUC)
of the cytosolic Ca2+ increase after addition of GPN to the
astrocytes was used to calculate the total amount of stored
calcium in these organelles. The results showed greater
AUC in APOE4 cells (Fig. 4d), supporting a higher con-
centration of lysosomal-related Ca2+ in APOE4 cells, as
compared to APOE3. Since there are no pharmacological
modulators of CAX, we relied on a pharmacological in-
hibitor of V-ATPase, bafilomycin A1, and on measure-
ments of pH in acidic organelles, to establish the
implication of the pump and CAX in the increased lu-
minal Ca2+. Bafilomycin A1 increased basal cytoplasmic
Ca2+ concentration in APOE4 astrocytes to 0.40 ± 0.05
(control values of astrocytes treated with vehicle were
0.30 ± 0.01; p-value = 0.05), whereas there was no effect on
non-stimulated intracellular Ca2+ levels in APOE3 (0.44 ±
0.08 for cells treated with bafilomycin A1 compared to
0.39 ± 0.02 of cells treated with vehicle). This suggests that
the aforementioned lower basal cytoplasmic Ca2+ concen-
tration in APOE4 cells is due to greater V-ATPase-
mediated Ca2+ uptake into acidic stores, consistent with
the greater intralysosomal Ca2+ levels revealed by the
GPN experiments. Accordingly, bafilomycin A1 reduced
the ATP-induced Ca2+ release in APOE4 astrocytes, con-
firming the dependence of these Ca2+ responses on acidic
stores (Fig. 4e). In contrast, bafilomycin A1 did not change
purinergic-induced Ca2+ responses in APOE3 astrocytes.
Thus, both basal levels and ATP responses in the presence
of bafilomycin A1 might indicate the existence of low V-
ATPase activity in APOE3 astrocytes. Indeed, the expres-
sion of V-ATPase subunit V0D1, which is highly expressed
in astrocytes [61], was higher in APOE4 cells than in
APOE3 cells (Fig. 4f). Because V-ATPase controls the flow
of H+ into acidic stores, we analyzed the pH of acidic
stores with the probe lysosensor and fluorometry. We
found that both APOE3 and APOE4 astrocytes had stand-
ard lysosomal-related pH, with a minimal but significant
difference of 0.14 pH units between genotypes, APOE4 ly-
sosomes being more alkaline (Fig. 4g). If the pH does not
decrease despite increased activity of the V-ATPase pump,
it follows that CAX activity must be increased in APOE4
astrocytes, too, such that the increased number of H+
entering the acidic stores exit through CAX in exchange
for Ca2+. As a result, lysosomal Ca2+ concentration and
hence basal Ca2+ and purinergic-induced Ca2+ release
from lysosomes, are greater in APOE4 than in APOE3
astrocytes. Note that we did not determine nor manipulate
CAX expression in APOE3 and APOE4 cells because the
sequence of mouse CAX is unknown.
APOE3 expression in APOE4 astrocytes reduces cytosolic
Ca2+ responses
Is the effect of APOE4 due to: (1) loss-of-function due to
decreased contents [62], (2) malfunction, (3) gain-of-
toxic function because of its structure, or (4) misplaced
intracellular localization? We first examined ApoE levels
in immortalized APOE3 and APOE4 astrocytes by quan-
tifying mRNA levels with qPCR. As shown in Fig. 5a,
APOE expression is lower in APOE4 than in APOE3 as-
trocytes. Therefore, it is plausible that lower expression
of APOE4 accounts for Ca2+ signaling alterations. To
test this possibility, we modulated the quantity of
APOE3 and APOE4 with the rationale that, if APOE ex-
pression matters, decreasing ApoE in APOE3 cells would
increase Ca2+ responses, whereas increasing ApoE in
APOE4 cells would decrease Ca2+ responses. Upon de-
creasing APOE expression in APOE3 astrocytes with an
APOE siRNA (Fig. 5b), ATP-induced Ca2+ responses
were still lower, as compared to APOE4 astrocytes, with
no differences observed between scramble- and siRNA-
transfected APOE3 cells (Fig. 5c). We also tried the
opposite strategy: we increased APOE expression using
GFP-APOE3 or GFP-APOE4 plasmids, which overex-
press a GFP-ApoE fusion protein, which then allows one
to identify cells with increased APOE expression (Fig.
5d). The GFP signal did not interfere with fura-2/AM
(data not shown). Because transfection efficiencies were
different among experiments (5 to 50% of GFP trans-
fected cells), we avoided inter-experimental variability by
normalizing peak Ca2+ responses to levels recorded in
APOE3 astrocytes transfected with a GFP-expressing
plasmid without APOE constructs. The over-expression
of GFP-APOE3, but not of GFP-APOE4, transformed
APOE4 into APOE3 astrocytes, in a statistically signifi-
cant manner (Fig. 5e), suggesting that Ca2+ hyperactivity
in APOE4 astrocytes is mainly due to the expression of
this particular isoform, but not to lower APOE expres-
sion. The data do not support, however, a gain of a toxic
function by APOE4, because, if this were the case,
APOE4-associated dysfunction would have been potenti-
ated by GFP-APOE4 over-expression, and would not
have been rescued by GFP-APOE3, since the toxic elem-
ent, APOE4, remained. In agreement, there were no dif-
ferences between ATP-induced Ca2+ signals in APOE3
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Fig. 5 Effects of the APOE allele vs APOE contents on Ca2+-based excitability. a APOE mRNA expression relative to Gapdh and 18S mRNA
contents in APOE3 and APOE4 immortalized astrocytes, quantified by real time qPCR (N = 3). b Representative ApoE western blot of APOE3 cells
transfected with scramble or APOE siRNA. c Representative traces and quantification of the magnitude of ATP-induced Ca2+ responses in APOE3
astrocytes transfected with lipofectamine (lipo), plus scramble (sc) or APOE siRNA, and APOE4 astrocytes treated only with lipofectamine (N = 4). d
Representative images of immunocytochemistry of APOE3 and APOE4 cells transfected with plasmids expressing GFP, GFP-APOE4, and GFP-APOE3,
as indicated. Scale bar represents 15 μm. e Representative traces and quantification of the magnitude of 100 μM ATP-elicited Ca2+ responses in
APOE3 and APOE4 cells transfected with different plasmids as indicated. Ca2+ peaks after ATP stimulation are relative to the responses of APOE3
cells transfected with GFP. Only GFP fluorescent cells were analyzed (at least 30 cells from 4 independent experiments). f Quantification of the
magnitude of Ca2+ responses elicited by 100 μM ATP in APOE3 astrocytes transfected with GFP or GFP-APOE4 plasmids, as indicated. Ca2+ peaks
after ATP stimulation are relative to the responses of APOE3 cells transfected with GFP. Only GFP fluorescent cells were analyzed (at least 30 cells
from 4 independent experiments). g Representative images of Lamp1 (red) and ApoE (green) immunocytochemistry in APOE3 cells. Merged
images and amplifications of the area in the white frame, are displayed. Scale bar represents 15 μm. h Representative images of Lamp1
immunocytochemistry (red) and GFP-ApoE fluorescence (green) in APOE4 cells. Merged images and the amplification of a cell of each image,
indicated with a white frame, are displayed. Scale bar represents 15 μm. Unpaired parametric T-test was used in a, and one-way ANOVA in c and
e. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****)
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cells transfected with GFP-APOE4 or with GFP (Fig. 5f),
again ruling out a toxic effect of APOE4. Taken together,
our data support APOE4 malfunction rather than
toxicity.
Finally, because acidic stores accounted for the differ-
ences in Ca2+ responses between genotypes, we studied
whether ApoE was localized in the acidic stores. Because
the quality of staining of such organelles with the fluoro-
phore lysotracker was not optimal for confocal studies
(data not shown), we resorted to using Lamp1, a marker
for lysosomes, autophagosomes, and different vesicles of
the endolysosomal pathway, including late-endosomes
[63]. In APOE3 astrocytes, we used ApoE and Lamp-1
immunostaining (Fig. 5g). In APOE4 astrocytes, we re-
lied on APOE4 overexpression with GFP-APOE4, since
the low amounts of APOE expression in APOE4 cells
precluded immunocytochemical analysis (Fig. 5h). We
observed that neither ApoE3 nor ApoE4 from GFP-
APOE4 colocalized with Lamp-1. These observations
rule out the likelihood that the alterations in lysosomal-
related Ca2+ handling in APOE4 astrocytes are due to
loss of a direct interaction of ApoE with channels medi-
ating Ca2+ fluxes, suggesting, instead, indirect actions of
the apolipoprotein, perhaps through changes in lipid
homeostasis.
ATP-induced Ca2+ responses are modulated by
extracellular lipids in APOE3 but not APOE4 astrocytes
Considering the wealth of evidence documenting how
channels and pumps involved in Ca2+ signaling are regu-
lated by lipids, particularly by membrane lipids [64, 65],
we posited that lipids regulate Ca2+ fluxes in astrocytes,
too, and that aberrant lipid homeostasis accounts for the
observed dysregulation of Ca2+ fluxes in APOE4 astro-
cytes, particularly in lysosome-related organelles. Lipid
modulation of Ca2+ transients in astrocytes is uncharted
territory. Thus, to gain insight into the control of astro-
cyte excitability by lipids in the context of APOE4, we
carried out two sets of experiments. First, we aimed to
obtain proof-of-concept that lipids regulate Ca2+ tran-
sients in astrocytes, by examining the effect of changing
lipid contents on the excitability of immortalized APOE3
and APOE4 astrocytes. Second, we analyzed cholesterol
subcellular distribution, and we performed a lipidomic
analysis of lysosomal and whole-membrane to identify
candidates for excitability-modulating lipids, and
changes thereof in the two genotypes.
Thus far, all our Ca2+ imaging experiments had been
performed in medium supplemented with FBS, rich in
nutrients, including lipoproteins. Here, we replaced this
medium with three different media with lower lipid
composition 2–5 min prior to Ca2+ imaging: 1) Krebs
medium (KH), 2) DMEM supplemented with
lipoproteins-deficient FBS and 3) DMEM with B27, a
supplement without lipoproteins and restricted compos-
ition of lipids: linoleic acid, linolenic acid, progesterone,
and corticosteroids. In the absence of lipids, non-
stimulated basal Ca2+ levels were significantly lower in
immortalized APOE4 vs APOE3 astrocytes, as detected
in the presence of lipids. Thus, in KH, basal levels were
0.29 ± 0.02 in APOE3 vs 0.23 ± 0.03 in APOE4 (p-value =
0.04); in DMEM supplemented with lipoprotein-
deficient FBS, 0.39 ± 0.07 in APOE3 vs 0.29 ± 0.06 in
APOE4 (p-value = 0.04); and in DMEM with B27, 0.30 ±
0.02 in APOE3 vs 0.22 ± 0.01 in APOE4 (p-value =
0.007). By contrast, in all three conditions, stimulation of
purinergic responses elicited Ca2+ responses of similar
magnitude in APOE3 and APOE4 astrocytes (Fig. 6a-c,
f). It was not the case that responses in APOE4 cells had
diminished, but, rather, that responses had increased in
APOE3 cells. That is, APOE4 astrocytes present the same
magnitude of ATP-induced Ca2+ signals regardless of
the lipids presents, whereas APOE3 astrocytes adapt
their Ca2+ responses to the concentration of extracellular
lipids, with responses being low in media rich in lipids
(presence of FBS) and high in the presence of low lipid
concentration, or no lipids. Consistent with the greater
ATP-triggered Ca2+ responses, the responses also lasted
longer in APOE3 astrocytes in the absence of lipids: the
response was 36.0 ± 4.0% of the maximum peak signal
after 20 s in KH, 51.6 ± 4.3% in DMEM supplemented
with lipoproteins-deficient FBS and 34.6 ± 3.0% in
DMEM with B27, as compared to the previously re-
ported 27.7 ± 1.5% in DMEM with FBS (p < 0.05). Thus,
the results point to a potentiation of long-lasting ampli-
fication Ca2+ pathways, perhaps by Ca2+-induced Ca2+
release from the ER or store-operated Ca2+ entry
(SOCE)—that is, Ca2+ influx across the plasma mem-
brane in response to depletion of intracellular Ca2+
stores. Still, ATP responses were significantly shorter (p-
value < 0.01) in lipid-depleted APOE3 astrocytes as
compared to APOE4 astrocytes (72.57 ± 3%, 68.4 ± 6.2%
and 81.2 ± 6.8% for APOE4 cells kept in KH, DMEM
with lipoprotein-deficient FBS and DMEM with B27),
indicating that some differences in Ca2+ fluxes remain
between APOE3 and APOE4 astrocytes.
It is worth stressing that the increased ATP-induced
Ca2+ response in APOE3 astrocytes is a fast-onset
process, as it was observed just a few min after lipopro-
tein removal. It is not transient, because it persisted 12 h
after replacement of DMEM supplemented with FBS for
DMEM supplemented with B27 (Fig. 6d and f), and it is
reversible, because it diminishes if the medium is re-
placed again by DMEM supplemented with FBS 5min
prior to Ca2+ recordings (Fig. 6e and f).
Altogether, three conclusions may be drawn from
these results: they constitute the first demonstration that
astrocyte excitability is modulated by lipids and/or
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lipoproteins, such regulation is reversible but stable in
APOE3 astrocytes as long as lipids remain present, and
is lost in APOE4 astrocytes.
The absence of lipids potentiates Ca2+ release from the
ER and extracellular Ca2+ entry in APOE3 but not APOE4
astrocytes
Since the core of Ca2+-signaling dysregulation in APOE4
astrocytes lies in acidic organelles, is Ca2+ homeostasis
in these organelles the target of extracellular lipids in
APOE3 astrocytes? The finding that the increase in
ATP-induced Ca2+ signals in APOE3 cells in the absence
of lipids/lipoproteins (KH media) was abrogated by Ned-
19, the inhibitor of Ca2+ release from acidic stores
(Fig. 7a) might indicate that extracellular lipids decrease
Ca2+ levels inside such organelles. Surprisingly, measure-
ment of Ca2+ stored inside acidic organelles using the
GPN-elicited depletion showed no increased Ca2+ load-
ing in APOE3 cells kept in KH (Fig. 7b) compared to
APOE3 astrocytes kept in the presence of FBS, whereas,
as expected, no difference was observed between the two
conditions in APOE4 astrocytes (Fig. 7c). An explanation
is that, in the absence of extracellular lipids, the release
of Ca2+ from lysosomes in APOE3 astrocytes is amplified
by the activation of other Ca2+ signaling mechanisms. In
fact, the amplification originates in part, from Ca2+
Fig. 6 Loss of modulation of Ca2+ signals by lipids in APOE4 astrocytes. Representative traces of 100 μM ATP-induced Ca2+ responses in APOE3
and APOE4 immortalized cells in (a) saline medium or Krebs medium (KH) for 2 to 5 min, (b) DMEM medium supplemented with lipoprotein-
deficient serum (Lipoprotein (−)) for 2 to 5 min, (c) DMEM medium supplemented with B27 for 2 to 5 min, and (d) overnight (ON), and (e) DMEM
medium supplemented with 10% FBS for 5 min. f Quantification of the ATP-induced intracellular Ca2+ peak in cells kept in the different mediums
(N = 3). Two-way ANOVA was used. p < 0.01 (**) as compared to APOE3 cells kept in the same medium
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released from the ER, because the Ca2+ content in the
ER was 1.5-fold greater in APOE3 cells kept in KH than
in DMEM/FBS, as recorded with the Ca2+ probe
CEPIA1er (Fig. 7d). The same amount of Ca2+ was re-
leased from the ER in APOE4 astrocytes kept in the two
media, in agreement with the observation that Ca2+ sig-
nals are independent of extracellular lipid concentrations
in this genotype (Fig. 7d). Another source of Ca2+ is the
extracellular Ca2+ entry, because the blockage of extra-
cellular Ca2+ with the cell-impermeable Ca2+ chelator
EGTA greatly reduced (by 3.3 times) ATP-induced Ca2+
responses in APOE3 astrocytes kept in KH without lipo-
proteins, but not in APOE3 astrocytes kept in KH with
FBS (Fig. 7e). In contrast, EGTA reduced ATP-induced
Ca2+ responses in APOE4 astrocytes to the same extent
in the presence or absence of FBS (Fig. 7f). Thus, the
data support the idea that extracellular Ca2+ entry is
secondary to lysosomal Ca2+ release, and that it is mod-
ulated by extracellular lipids in APOE3 but not in
APOE4 astrocytes. We next sought morphological
Fig. 7 Loss of lipid-dependent coordination of Ca2+ fluxes across plasma and lysosomal membranes in APOE4 immortalized astrocytes. a
Representative traces and quantification of the magnitude of ATP- triggered intracellular Ca2+ responses in cells treated with DMSO or with
100 μM Ned 19 for 20 min in KH medium (N = 3). b, c Representative traces and quantification of lysosomal Ca2+ content measured as AUC after
200 μM GPN addition to (b) APOE3 and (c) APOE4 astrocytes in KH medium, as compared to DMEM medium supplemented with FBS (FBS) (N = 3)
(FBS-related results were presented in Fig. 3); d Representative traces and quantification of Ca2+ ER release in 100 μM ATP-stimulated astrocytes
transfected with G-CEPIA1er, and kept in KH medium supplemented or not with FBS (N = 4). e, f Representative traces and quantification of
purinergic-induced Ca2+ responses in (e) APOE3 and (f) APOE4 astrocytes in KH medium supplemented with 10% of FBS with or without Ca2+/1
mM EGTA for 10 min, and KH medium with Ca2+ or without Ca2+/500 μM EGTA for 1 min. g Representative images from Lamp1
immunofluorescence of both cell lines and quantification of the percentage of lysosomes in different ranges of distance, the 0 value being the
nucleus in each cell. (N = 3, 30 to 40 cells quantified). Scale bar represents 15 μm. One-way ANOVA was used in sections a, d, e and f, unpaired
parametric T-test in b and c, and two-way ANOVA in g. p < 0.05 (*), p < 0.001 (***), p < 0.0001 (****)
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support for this idea by studying the localization of
acidic stores inside astrocytes. Again, we resorted to
Lamp1 immunostaining to be able to use confocal
microscopy. Lysosome distribution was abnormal in
APOE4 cells (Fig. 7g); that is, a greater number of
Lamp1-positive organelles accumulated near the nucleus
in APOE4 astrocytes than in APOE3 astrocytes. Specific-
ally, 37% of lysosomes are placed at 10 μm from the
center of the nucleus in APOE4 cells, as compared to
21% in APOE3 astrocytes. Plausibly, the altered
localization may result in changes in the coupling of
such organelles with plasma-membrane channels.
In summary, in APOE3 astrocytes, activation of extra-
cellular Ca2+ entry secondary to intracellular Ca2+
mobilization underlies the greater Ca2+ responses
induced by purinergic receptors in the absence of extra-
cellular lipoproteins. This coordination of signaling
pathways does not take place in the presence of lipopro-
teins, suggesting, again, that lipids have the capacity to
change intracellular Ca2+ fluxes in APOE3 astrocytes. By
contrast, APOE4 astrocytes present a higher content of
lysosomal Ca2+, but appear to have lost the capacity to
have Ca2+ fluxes regulated by lipids.
Lipidomics reveals distinct lipid composition in lysosomal
and whole-cell membranes from APOE3 and APOE4
astrocytes
We posited that lysosomal dysregulation and the refrac-
toriness to lipid-based modulation in APOE4 astrocytes
might be caused by altered lipid trafficking and homeo-
stasis due to APOE4 malfunction—as concluded in a
previous section. Since ApoE is a major cholesterol
carrier in the brain, we studied cellular cholesterol distri-
bution with filipin staining. We found aberrant intracel-
lular distribution of cholesterol in APOE4 astrocytes,
which presented more cholesterol in intracellular
clumps, and less in plasma membrane, than APOE3 cells
(Fig. 8a). This finding points to impaired cholesterol ef-
flux in APOE4 cells. We also carried untargeted lipido-
mics because we reasoned that impaired lipid trafficking
would leave its mark on astrocyte membranes, such that
the profiling of membrane lipids would provide informa-
tion about lipid dyshomeostasis in APOE4 astrocytes. To
determine whether APOE4-mediated changes were spe-
cific to lysosomes, we performed lipidomics in lysosomal
and whole-membranes of APOE3 and APOE4 immortal-
ized astrocytes, since, according to a lipid map of the
mammalian cell, organelles present distinct lipid compo-
sitions [66]. The multivariate analysis PLS-DA revealed
that the lipids of lysosomal membranes (Fig. 8b) and
whole-membranes (Fig. 8c) clustered independently in
APOE3 and APOE4 genotypes. The predictive accuracy
of the analysis was robust, as the Q2 and R2Y scores
were 0.616 and 0.986 for lysosome lipidome, and 0.841
and 0.995 for whole-membranes. The PLS-DA analysis
thus confirms that APOE genotype influences membrane
lipid composition in astrocytes.
In order to identify which lipids contributed more to
the differential group clustering, we used the Variable
Importance in the Projection (VIP), such that lipids with
VIP > 1 were the ones with greater weight on the group
change. In lysosomal membranes, there were 35 lipids
with VIP > 1 in the APOE4 vs APOE3. ANOVA analysis
with a Tukey correction post-test of the intensity (peak
values) of these 35 metabolites revealed significant dif-
ferences due to the APOE phenotype with a p-value <
0.05, confirming, again, that expression of APOE4 alters
the lipidome of lysosomes. We then proceeded to identi-
fication of the particular metabolites and calculation of
their fold change (FC) in APOE4 vs APOE3 astrocytes.
We could identify 19 lipids: 10 phosphatidylcholines (6
increased, 4 decreased), 5 phosphatidylethanolamine (2
increased, 3 decreased), 2 lysophosphatidylcholine (2 de-
creased), 1 lysophosphatidylethanolamine (decreased),
and 1 carnitine (increased) (Fig. 8d). However, multi t-
test analysis corrected by a false discovery rate (FDR) of
these 19 FC values gave no statistically significant differ-
ences (q-value < 0.05). This suggests that joint changes
in the contents of lipids with VIP > 1 rather than par-
ticular lipids account for the segregation of lipidomes
from APOE3 and APOE4 lysosomes.
In whole-membranes, 41 metabolites had a VIP > 1,
comparing APOE4 vs APOE3 astrocytes. ANOVA ana-
lysis with a Tukey correction post-test of the intensities
of these 41 metabolites confirmed significant differences
due to the APOE phenotype with a p-value < 0.01, in
agreement with the previous PLS-DA analysis. Twety-
one lipids were identified according to their m/z, and
their FC in APOE4 vs APOE3 calculated (Fig. 8e). A
multi T-test statistical analysis corrected with FDR,
showed that 11 of these metabolites were significantly
different (q-value < 0.05): 3 lysophosphatidylcholine (1
increased, 2 decreased), 5 phosphatidylcholines (3 in-
creased, 2 decreased), 1 phosphatidylserine (decreased)
and 2 carnitines (increased). In short, a general trend is
that carnitines and phosphatidylcholines are more abun-
dant in APOE4 astrocytes, whereas APOE3 cells are
richer in lysophospholipids.
Overall, this is the first demonstration that the
expression of APOE4 changes the lysosomal and
cellular lipidomes in astrocytes, supporting a link be-
tween altered Ca2+ fluxes and lipid dyshomeostasis.
It is worth noting that the different intracellular
distribution of cholesterol in APOE3 and APOE4
astrocytes is not due to differences in cholesterol
contents between the two genotypes, as the VIP for
cholesterol was consistently lower than 1 in the lipi-
domes (data not shown).
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Discussion
The study has two main general findings. First, in im-
mortalized mouse astrocytes expressing human APOE3
and APOE4 we found that APOE4, in comparison to
APOE3, increases receptor-induced Ca2+ responses due
to increased release of Ca2+ from acidic organelles,
which integrate lysosomes and related organelles.
Further, APOE4-expressing astrocytes present distinct
lipid profiles and are refractory to Ca2+-signaling regula-
tion by lipids (model in Fig. 9). Second, Ca2+ hyperactiv-
ity associated with the APOE4 allele was also found
ex vivo in astrocytes from targeted replacement male
mice, but not in females, whose astrocytes showed
increased Ca2+ responses in APOE3 mice, matching
those in APOE4 mice. Below we discuss the possible
links between dysregulation of Ca2+ signaling, lipid sig-
naling and lipid homeostasis in astrocytes, and the impli-
cations in neurodegenerative diseases in which APOE4 is
a risk factor in both men and women.
Mechanistically, a key finding is that the pH of acidic
organelles is similar in immortalized APOE4 and APOE3
astrocytes, despite greater expression and activity of the
lysosomal H+ pump V-ATPase, supporting the idea that
the pH is maintained due to an antiparallel transport of
Fig. 8 Different lipid profiles in lysosomal and whole-cell membranes from APOE4 vs APOE3 astrocytes. a Cholesterol accumulation visualized by
Filipin III staining in immortalized APOE3 and APOE4 astrocytes (N = 2). Scale bar represents 100 μm. The white squares are amplified in the top
right images. b, c PLS-DA analysis of lysosomal (b) and whole-cell membranes (c) from APOE3 and APOE4 immortalized astrocytes. Each dot is an
individual sample. d, e Representation of changes of lipids with VIP > 1 identified in lysosome (d) and whole-cell (e) membranes as logarithm
base 2 of fold changes of intensities in APOE4 vs APOE3. Positive values indicate increase and negative values decrease in APOE4 vs APOE3 cells.
q < 0.05 (*), q < 0.01 (**), multi T-test analysis corrected by false discovery rate (FDR)
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H+ and Ca2+ that extrudes H+ and takes up Ca2+ via
CAX. Thus, it is plausible that CAX expression and/or
activity are increased in APOE4 astrocytes, too. In conse-
quence, APOE4 acidic stores have greater Ca2+ content,
and hence release more Ca2+ upon purinergic activation.
Coordination between intracellular signaling pathways
translates the increased Ca2+ mobilization from acidic
vesicles to an increased Ca2+ released from ER, and a
higher Ca2+ uptake into the mitochondria. In accordance
with most studies in the field [36–38, 51, 58–60, 67–69],
we considered this heterogeneous population of acidic
vesicles as a whole, but we cannot rule out specific dif-
ferential traits in a particular kind of acidic vesicle. For
example, a recent report described differences of pH be-
tween the endolysosomal systems of APOE3 and APOE4
astrocytes [70], suggesting that greater pH differences
than that detected in our study may exist between geno-
types, depending on the compartment analyzed.
It is worth stressing that APOE4 expression not only
alters Ca2+ uptake and mobilization from acidic stores,
Fig. 9 Summary of the Ca2+ signaling alterations in APOE4 astrocytes. a) Ca2+ signaling pathway of APOE3 (a) and APOE4 (b) astrocytes in the
presence (left) or absence (right) of extracellular lipids. The name of channels and receptors that increase cytosolic Ca2+ are in blue rectangles,
whereas pathways decreasing cytosolic Ca2+ are in green rectangles. The size of the arrows indicates if the process is increased with respect to
APOE3 astrocytes in the presence of extracellular lipids. Plasma-membrane lipids and lipoproteins are shown in different colors in APOE3 and
APOE4 astrocytes to reflect their different lipid composition. Organelle and plasmatic membrane graphs were obtained from Smart Servier
Medical Art (https://smart.servier.com/)
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but also promotes general dysregulation of these organ-
elles in astrocytes, including higher perinuclear lysosome
localization and changes in the overall lysosomal lipi-
dome. The intracellular localization of lysosomes, which
is determined by factors such as phospholipids and
cholesterol, is linked to many of their functions and
pathology [71, 72], although such studies have only been
performed in cultured cells, plausibly due to the diffi-
culty of tracking the tortuous intracellular distribution
of the endolysosomal system in whole tissues. Specific-
ally, our study confirms the previous observation that
aberrant accumulation of cholesterol conditions pro-
motes perinuclear clustering of lysosomes [71]. On the
other hand, our results showing aberrant intracellular
cholesterol accumulation, together with alterations of
phospholipid composition in cellular membranes in
APOE4 astrocytes, point to dysregulation of the forma-
tion, internalization, and degradation of lipoproteins,
processes in which lysosomes and related acidic vesicles
participate [73]. Moreover, alterations of cholesterol traf-
ficking and intracellular cholesterol accumulation have
been linked to impaired autophagy [74]. Accordingly,
impaired autophagy [75] and reduced lysosome-
dependent amyloid degradation [76] have been reported
in immortalized APOE4 astrocytes, and in astrocytes de-
rived from APOE4 iPSC, respectively. Transcriptome
analyses of whole brains of aged APOE4 targeted re-
placement mice also revealed dysregulated expression of
genes related to the endolysosomal system, although the
contributions of the different cellular types were not
studied [77]. Dysregulation of Ca2+ homeostasis might
be a cause rather than a consequence of lysosomal dys-
function, as there is evidence supporting Ca2+ release
from acidic stores controlling endolysosomal trafficking
and autophagy [67, 78]. Moreover, in astrocytes, it has
been reported that NAADP-induced Ca2+ release from
lysosome-like organelles increases autophagic markers
[79], and inhibits the fusion of the autophagosome with
lysosomes, thus arresting the autophagic fluxes [69].
An unexpected discovery of this study is that lipopro-
teins modulate the magnitude of ATP-induced cytosolic
Ca2+ responses in APOE3 astrocytes by changing the
interplay of Ca2+ signaling and fluxes among organelles
and the plasma membrane. The observation that the
down-regulation of purinergic-induced Ca2+ responses
in the presence of lipids is quick and reversible rules out
the implication of gene expression and down-regulation
of purinergic receptors. Rather, the phenomenon sup-
ports the emerging notion of lipid-mediated control of
Ca2+ channels. Precedents are the activation by lysopho-
sphatidylcholine of astrocytic extracellular Ca2+ entry
[80], and the regulation by lipids of some of the channels
responsible for SOCE. Specifically, cholesterol regulates
TRPC1 in neutrophils [81] and STIM in pulmonary
endothelial cells [82], whereas phosphoinositides regu-
late TRPC3,6,7 channels in numerous cell types [83].
Recently, very-low-density lipoproteins have been shown
to inhibit STIM in atrial myocytes [84]; this study and
ours are the first to report lipoproteins regulating Ca2+
signaling. It is worth stressing that the all-or-nothing
experimental design consisting in testing the effects of
media with and without lipoproteins allowed us to
obtain proof of concept that lipoproteins modulate Ca2+
excitability in astrocytes, but in physiological settings,
Ca2+ signaling in astrocytes is, plausibly, modulated by
subtle changes in brain lipid contents.
Importantly, lipoprotein-mediated regulation of puri-
nergic Ca2+ signaling is lost in APOE4 astrocytes. Several
factors could explain this finding. First, the accumulation
of lysosomes around the nucleus may uncouple the lyso-
somal Ca2+ release and SOCE. Second, the entry of
extracellular Ca2+ triggered by low levels of Ca2+ inside
acidic vesicles requires the TPC2 channels of acidic vesi-
cles, which are less expressed in APOE4 than in APOE3
astrocytes. Third, Ca2+ inside the acidic stores is higher
in APOE4 astrocytes compared to APOE3 cells; hence
SOCE mechanisms may not be triggered after
purinergic-induced lysosomal Ca2+ release. Fourth,
APOE4 astrocytes may be devoid of the right concentra-
tion of lipids to modulate lysosomal and Ca2+ entry
channels, as they have different lysosomal and cellular
lipidomes compared to APOE3 cells. Specifically, the de-
creased contents of lysophosphatidylcholine species in
APOE4 vs APOE3 cellular membranes may explain the
uncoupling of Ca2+ fluxes in APOE4 astrocytes, for these
lipids activate SOCE [80], and the cation TRPV2 channel
[85] in astrocytes. Moreover, the increase in phosphati-
dylcholines in APOE4 lysosomes is consistent with the
observed potentiation of NAADP-mediated Ca2+ release,
since, as noted, phosphatidylcholines stimulate this path-
way [65]. Finally, the decrease in plasma membrane
cholesterol in APOE4 astrocytes compared to APOE3
cells may underlie the reduced SOCE activation, because
SOCE requires cholesterol in different cell types [81, 82,
86]. Cholesterol alterations have been also reported in
human APOE4-iPSC derived astrocytes [76], and in
brains from 12-month-old APOE4 mice [87]. Interest-
ingly, cholesterol synthesis is decreased in astrocytes
upon aging [88], which might exacerbate APOE4-elicited
lipid dyshomeostasis and Ca2+ signaling.
Remarkably, the differences in Ca2+ signaling between
APOE4 and APOE3 astrocytes were also detected ex vivo
in 9–12-week-old male but not in female mice, suggesting
that the APOE allele affects astrocyte excitability in a sex-
dependent manner. The present study thus adds to the in-
creasing evidence of complex interactions between APOE
genotype and sex, as shown, for example, in lipid-related
metabolic variations [89], cerebrovascular pathology [90],
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and tau levels in the cerebrospinal fluid [91]. The follow-
ing scenarios might explain the sex bias in astrocyte excit-
ability in different APOE alleles. First, Ca2+ signals in
female astrocytes might be by default higher, regardless of
the APOE allele. Along these lines, a recent study showed
greater estradiol-induced Ca2+ signals in astrocytes from
female mice than from male astrocytes [92]. Second, the
down-regulation of Ca2+-based excitability by lipids ob-
served in immortalized APOE3 astrocytes might not occur
in females. Note that ex-vivo Ca2+ responses in female
mice resemble Ca2+ responses in immortalized astrocytes
in the absence of lipoproteins. Emerging evidence indeed
points to a distinct impact of APOE genotype on brain
lipid metabolism [76, 87] with a sex bias [93]. In the latter
study, lipid clustering by principal component analysis of
cortical lipidomes unravels sample segregation by sex in
APOE3 but not in APOE4 16month-old mice [93]. That
is, sex differences were observed in APOE3 but not in
APOE4 mice, as in our study. Specifically, there was a
trend for greater concentrations of phosphatidylcholines
and lysophosphatidylcholines in APOE3 male than in
APOE3 female mice [93]. Taking together these and our
results, it is plausible that the interplay of sex, APOE geno-
type and age differently shapes the composition of lipid
milieus in male and females through life, resulting in dis-
tinct astrocytic Ca2+ responses.
Whatever the case, our study supports that immortal-
ized astrocytes from human APOE replacement mice
may be a model to understand APOE4 pathology in
males. The fact that Ca2+-based astrocyte excitability
controls neural functions [94] lends credence to the hy-
pothesis that APOE4-elicited dysregulation of Ca2+
fluxes in astrocytes contributes to the impairment of
brain activity and metabolism in the healthy brain, as re-
peatedly reported in humans [4–6, 8], although, of note,
no sex-based stratification existed in these studies. It is
worth noting that the differences in APOE genotype
were observed in 10-week old male mice, pointing to
early detrimental actions of APOE4 in brain, not surpris-
ingly so, for APOE alleles are acquired at conception.
This is important because, although metabolic alter-
ations and distinct patterns of brain activity have been
reported in young humans harboring APOE4 [95, 96],
and olfactory-memory impairment exists in 6 month-old
APOE4 mice [13, 89], most studies with human APOE4
gene targeted replacement of murine APOE have been
conducted with aged mice, and occasionally, middle-
aged (over 10 months) rodents [97].
We emphasize that the APOE4 phenotype observed in
the aforementioned studies, as well as in our study, oc-
curs in the absence of LOAD pathology, although it may
render brains more vulnerable to age-dependent
ailments. Thus, a wealth of data suggests that APOE4 ex-
acerbates the impairment of Aβ processing and
clearance caused by ApoE, leading to increased accumu-
lation, and hence aggregation, of Aβ in the brain [70]. In
addition, ApoE4 has recently been reported to potentiate
Tau-mediated neurodegeneration independently of Aβ
[24]. However, it is increasingly more recognized that al-
terations in lysosomal functions [98], lipid homeostasis
[99], and Ca2+ signaling play a role in LOAD, too. The
Ca2+ hypothesis in LOAD contends that aberrant Ca2+
responses in neurons associated with Aβ, Tau, and the
glutamatergic system underlie cognitive impairment
[100]. In addition, Ca2+ signaling is profoundly dysregu-
lated in astrocytes in animal models of AD [39, 101],
mainly due to aberrant activation of purinergic receptors
[56]. Our results support the notion that APOE4 may
exacerbate the dysregulation of Ca2+ signaling in male
astrocytes in LOAD owing to lysosomal dysfunction
caused by lipid dyshomeostasis. Dysregulation of astro-
cyte excitability in LOAD may, in turn, contribute to
neural-circuit hyperactivity independently of Aβ and
Tau pathologies [102], supporting astrocytic-lysosome
targeted therapies in LOAD, at least in male patients.
An outstanding question in APOE4-targeted therapeu-
tics is whether the mutated domain renders ApoE4
toxic, or less efficient, than ApoE3 and ApoE2. Alterna-
tively, since ApoE is lower in cerebrospinal fluid (CSF)
of APOE4 individuals [62], and in plasma, CSF, and
brain tissue of APOE3 and APOE4 as compared with
APOE2 targeted replacement mice [103], is it the prob-
lem that ApoE4 is less abundant? The answers to these
questions are important because they will determine
whether therapeutic strategies should be aimed to in-
crease or decrease ApoE production, or to replace
APOE4 with APOE3 or APOE2. It seems unlikely that
the effects of APOE4 on lysosomal-related Ca2+ fluxes
are due to decreased expression of APOE4, because
APOE4 over-expression did not revert Ca2+ responses to
the levels observed in APOE3 cells. It is also unlikely
that the APOE4 phenotypes are caused by direct inter-
action between ApoE4 and V-ATPase and/or NAADP
receptors in the acidic organelles, as shown for APOD,
another brain apolipoprotein that participates in vesicle-
mediated astrocyte-to-neuron communication [104] and
prevents lysosomal membrane permeabilization [51],
given that our immunocytochemistry showed scarce
ApoE in astrocytic lysosomes. Rather, the data support
malfunction of ApoE4, which could be rescued by over-
expression of APOE3, as shown here, and perhaps
APOE2 [50]. Whether drugs designed to increase ApoE4
lipidation in order to enhance the capacity of the lipo-
protein to carry cholesterol [105] would restore intracel-
lular lipid dyshomeostasis in astrocytes is an open
question, since the mechanisms whereby the APOE allele
modifies lipid contents and distribution in astrocyte
membranes remain to be explored. Alternatively,
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because APOE4 exacerbates ApoE-mediated Aβ aggrega-
tion [70] and Tau pathology [24], ApoE removal is being
pursued by immunotherapy [106]. However, considering
the pleiotropic functions of APOE as a lipid carrier be-
tween cells, and plausibly inside cells, chronic removal
of ApoE may have secondary effects. All in all, develop-
ment of APOE4-specific therapeutics is in order. To this
end, better understanding of the basic biology of APOE,
and of the particulars of APOE4 action and sex bias in-
dependently of Aβ and Tau, are necessary. Overall, our
findings that APOE4 per se disrupts the lipid-based
regulation of Ca+ 2 fluxes in astrocytes due to lysosomal
dysregulation supports the notion that astrocyte
dysfunction contributes to APOE4 pathology in
neurodegeneration.
Conclusions
Taking together ex vivo and in vitro data, we conclude
that APOE4 malfunction augments Ca2+-based excitabil-
ity in astrocytes due to dysregulation of calcium fluxes
in and out the lysosome, associated with lipid dysho-
meostasis, and that the phenomenon might be male-
associated. One implication of the study is that it
supports the use of therapies aimed to restoring lyso-
somal dysfunction in astrocytes, including targeted over-
expression of APOE3 or APOE2, in order to halt the
accelerated progression of LOAD in male APOE4 car-
riers. Since Ca2+ signaling is central to the regulation of
neural circuits by astrocytes, another implication of the
study is that the therapeutic correction of astrocyte ex-
citability might reverse the neural-circuit hyperactivity
observed in APOE4-harboring humans and mice in the
absence of Aβ and Tau pathologies. Finally, clarifying
the sex bias in the efficacy of APOE4 targeted therapeu-
tics is a must, for the mechanisms underlying APOE4
pathology might differ in males and females.
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